Patent number: 12077546
Abstract: The present disclosure provides bicyclic pyridine derivatives. A compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein X is a oxygen atom, sulfur atom, NR, or CR?R?, n is 0 or 1, R1, R2a, R2b, R2c, R2d, R, R? and R? are each independently a hydrogen atom, a halogen atom, optionally substituted C1-6 alkyl, or an optionally substituted C6-10 aryl, or two of R2a, R2b, R2c, R2d, R, R?, and R?, together with a carbon atom or a nitrogen atom to which they are attached, form a 3- to 6-membered saturated carbocyclic ring or saturated heterocyclic ring, and R3a, R3b, R3c and R5a and R5b, are as defined in the description.
Type:
Grant
Filed:
November 10, 2023
Date of Patent:
September 3, 2024
Assignee:
Sumitomo Pharma Co., Ltd.
Inventors:
Satoshi Adachi, Hidefumi Yoshinaga, Hajime Shibata, Yusuke Shioda, Riko Nagahama
Publication number: 20240287079
Abstract: A 6-aminopyrazolopyrimidine compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided. A compound of Formula [IA]: or a pharmaceutically acceptable salt thereof, wherein a partial structure: is a structure of the following formula: etc. wherein R4 is hydrogen or C1-4 alkyl, in which the alkyl may be optionally substituted with hydroxy or cyano, Ring group CyA is a group of the following formula: etc. wherein R6 and R7 are, each independently, hydrogen, hydroxy, cyano, C1-6 alkyl, etc., R8 and R9 are, each independently, hydrogen, C1-4 alkyl, or C1-4 haloalkyl, R10 is hydrogen, cyano, C1-6 alkyl, etc.), R1 is hydrogen or C1-4 alkyl, R2A and R3A are, each independently, hydrogen, C1-6 alkyl etc.
Type:
Application
Filed:
August 30, 2022
Publication date:
August 29, 2024
Inventors:
Yusuke Ohba, Kaoru Adachi, Tatsuya Nishimaru, Kentaro Sakurai, Yosuke Ogoshi, Shimpei Sato